As a medical physicist, I use quantitative analysis to unravel the complexities associated with image interpretation, radiation dosimetry, assessing the biological effects of radiation, and evaluating the clinical utility of radiation therapy.
My clinical and research interests are based on tumor imaging and therapy with radiolabeled molecules, which have the potential to increase the specificity and sensitivity of imaging techniques to identify tumors and cancer cells. In the therapeutic context, this approach may improve our ability to deliver radiation or other bioactive treatments to cancer cells that have spread throughout the body, including those that cannot be identified with imaging.
My recent studies have focused on imaging the tumor microenvironment (especially oxygen deficiency, or hypoxia); imaging metastatic prostate, colorectal, renal cell tumors with radiolabeled monoclonal antibodies; and using the alpha particle-emitting agent Radium-223 dichloride to treat prostate cancer that has metastasized to bone.
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Joseph O'Donoghue discloses the following relationships and financial interests:
Janssen Research & Development, LLC
Provision of Services
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.